Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tito Fojo

Showing results (21-30 of 237) with videos related to

Pageof 24
Sort By:
The Journal of Clinical Endocrinology and Metabolism|October 10, 2008
Adjuvant mitotane for adrenocortical cancer--a recurring controversyHui Huang, Tito Fojo
Cell Cycle (Georgetown, Tex.)|November 14, 2002
Arsenic trioxide (As(2)O(3)): still a mysteryTito Fojo, Susan Bates
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survivalJulia Wilkerson, Tito Fojo
The Lancet. Oncology|December 4, 2010
Bevacizumab and breast cancer: the E2100 outlierTito Fojo, Julia Wilkerson
JAMA Oncology|May 22, 2025
Skimming the Median and the Problem of Exaggerated Survival GainsTito Fojo, Susan Bates
Seminars in Oncology|December 21, 2010
Practical considerations in the evaluation and management of adrenocortical cancerSanjeeve Balasubramaniam, Tito Fojo
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?Olivier Rixe, Tito Fojo
Journal of the National Cancer Institute|July 1, 2009
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion questionTito Fojo, Christine Grady
Cancer Discovery|January 16, 2013
Mechanisms of resistance to PARP inhibitors--three and countingTito Fojo, Susan Bates
Oncogene|October 25, 2003
Strategies for reversing drug resistanceTito Fojo, Susan Bates
Pageof 24

Showing results (21-30 of 237) with videos related to

Sort By:
Pageof 24
The Journal of Clinical Endocrinology and Metabolism|October 10, 2008
Adjuvant mitotane for adrenocortical cancer--a recurring controversyHui Huang, Tito Fojo
Cell Cycle (Georgetown, Tex.)|November 14, 2002
Arsenic trioxide (As(2)O(3)): still a mysteryTito Fojo, Susan Bates
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survivalJulia Wilkerson, Tito Fojo
The Lancet. Oncology|December 4, 2010
Bevacizumab and breast cancer: the E2100 outlierTito Fojo, Julia Wilkerson
JAMA Oncology|May 22, 2025
Skimming the Median and the Problem of Exaggerated Survival GainsTito Fojo, Susan Bates
Seminars in Oncology|December 21, 2010
Practical considerations in the evaluation and management of adrenocortical cancerSanjeeve Balasubramaniam, Tito Fojo
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?Olivier Rixe, Tito Fojo
Journal of the National Cancer Institute|July 1, 2009
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion questionTito Fojo, Christine Grady
Cancer Discovery|January 16, 2013
Mechanisms of resistance to PARP inhibitors--three and countingTito Fojo, Susan Bates
Oncogene|October 25, 2003
Strategies for reversing drug resistanceTito Fojo, Susan Bates
Pageof 24